This job has expired

You will need to login before you can apply for a job.

Summer Intern - Analytical Development

Precision BioSciences, Inc.
Durham, NC
Start date
Feb 2, 2023

View more

Information Technology, Business/Data Analytics
Required Education
Bachelors Degree
Position Type
Full time
Bio NC

Job Details



Precision BioSciences Summer Internship Program allows current students the opportunity to complete a combination of larger projects to solve a key problem and day to day tasks to better understand what a career in the given field entails. Interns will also participate in group learning and networking opportunities and enhance presentation skills through a capstone presentation at the end of the summer.


This position is a full-time internship, working 32-40 hours per week for approximately 12 weeks in the summer.


The Analytical Development, Molecular Assay Team Intern will assist in optimization of cell culture and cell processing workflows that will serve as upstream starting points for a cell-based potency assay required for a gene therapy product. This project will define the optimal parameters for the current cell-based potency assay readout via ddCPR, and will also provide a framework that will be used to inform future potency assays for other products. The Intern will gain experience in lab-based skills such as cell culture, delivery of gene-editing drug substances/drug products, and ddPCR. In addition, the Intern will gain (or continue to build) an understanding of experimental design (including DOE-based approaches) and the guidelines that regulate development of analytical methods in industry.


**Please note, Precision BioSciences mandates COVID-19 vaccination of all employees. Accommodations may be made in accordance with applicable law.


Essential Duties and Responsibilities

Reasonable accommodations may be made to enable individuals with disabilities to perform the essential functions of this position.  This list contains the major duties and requirements of the job and is not all-inclusive. Incumbent(s) may be expected to perform role-related duties other than those contained in this document.


  • Execute established assays and analyze data according to SOPs
  • Perform Aseptic cell culture with immortalized and genetically altered cell lines
  • Utilize such techniques as DNA/RNA extraction, ddPCR, qPCR, and statistical analysis
  • Work collaboratively with others as part of a coordinated team
  • Maintain an electronic notebook to document all experiments in a timely fashion
  • Follow all internal SOPs and policies



The requirements listed below are representative of the knowledge, skill, and/or ability required to perform this job successfully.


  • Currently enrolled in an accredited university program with at least three years of completed undergraduate studies in molecular biology, cell biology, or related field; or MS or PhD candidate or equivalent combination of education and experience
  • Familiar with general laboratory setting/equipment, including pipettes and centrifuge
  • Hands-on experience in general lab techniques, like aseptic cell culture



  • Experience in gene editing
  • Hands-on experience with molecular analytical techniques such as end-point PCR, qPCR, and/or dPCR
  • Familiarity with genomic-based applications for qPCR/dPCR (e.g. copy number variation
  • Running and analyzing data from ddPCR and qPCR readouts, and general experience with statistical software
  • Familiarity with GLP practices and documentation  
  • Experience with data analysis and presentation tools like Excel, Prism, and JMP



Travel Requirements

  • This position requires no travel.


  • This is a primarily office-based position associated with the main headquarters in Durham, NC.



Precision BioSciences, Inc. (Nasdaq: DTIL), is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. This isn’t just a statement supporting the products that we’re developing – it’s a statement that speaks to our collective desire to do our part in improving the lives of those around us. ARCUS is a highly specific and versatile genome editing platform designed with therapeutic safety, delivery, and control in mind. Using ARCUS, Precision is developing allogeneic CAR T and in vivo gene correction therapies for cancer and genetic diseases. Our team includes pioneers in genome editing, leaders in business, and a full staff of talented and committed people who are excited to be a part of medical and scientific breakthroughs.  For additional information, please visit www.


Precision BioSciences actively fosters an inclusive environment to ensure we attract and retain the best talent; we value diversity of life experiences and perspectives; and we encourage innovation in pursuit of our mission.  We provide equal employment opportunities (EEO) to all employees and applicants for employment without regard to race, color, religion, gender, sexual orientation, gender identity or expression, national origin, age, disability, genetic information, marital status, amnesty, or status as a covered veteran in accordance with applicable federal, state and local laws. Precision BioSciences complies with applicable state and local laws governing non-discrimination in employment in every location in which the company has facilities. This policy applies to all terms and conditions of employment, including, but not limited to, hiring, placement, promotion, termination, layoff, recall, transfer, leaves of absence, compensation, and training.


Precision BioSciences, Inc. (Nasdaq: DTIL) is a clinical stage gene editing company developing in vivo gene editing and ex vivo allogeneic CAR T therapies with its highly precise and versatile ARCUS genome editing platform. ARCUS uses sequence-specific DNA-cutting enzymes, or nucleases designed for gene knock out, as well as highly sophisticated edits for gene insertion and/or gene repair. Precision’s in vivo gene editing pipeline consists of wholly-owned preclinical candidates for primary hyperoxaluria type 1 (PBGENE-PH1), familial hypercholesteremia (PBGENE-PCSK9) and chronic hepatitis B (PBGENE-HBV). It has also partnered with Lilly to develop candidates for Duchenne muscular dystrophy and two other programs targeting the liver and CNS. Precision’s allogeneic CAR T pipeline consists of multiple investigational candidates in early-stage clinical trials, including its first and second generation CD19 targeting candidates PBCAR0191 and PBCAR19B for relapsed and/or refractory (R/R) non-Hodgkin and B-cell lymphoma patients. Precision has also prioritized development of PBCAR269A, its BCMA targeted candidate in combination with a gamma secretase inhibitor for R/R patients with multiple myeloma. Precision BioSciences and its in-house manufacturing facility for AAV, mRNA, and CAR T cells is based in Durham, North Carolina. For more information about Precision BioSciences please visit

Stock Symbol: DTIL

Stock Exchange: NASDAQ

Find Us
302 East Pettigrew Street
North Carolina

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert